DARGAN CHARLES K 4

What Happened
Charles K. Dargan, who serves as Chief Financial Officer of BioLargo, Inc. (BLGO), was granted an option award covering 300,000 shares on February 1, 2026. The Form 4 reports this as an award/derivative transaction (code A). No per-share exercise price or cash value is provided in the filing (listed as N/A), so total value and vesting/exercise terms are not specified in the document.

Key Details

• Transaction date: 2026-02-01 (reported on Form 4 filed 2026-02-03). Filing appears timely (within SEC two-business-day window).
• Transaction type: Option grant / award (derivative) — 300,000 shares; price/exercise amount: N/A (not disclosed).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The option was issued as compensation for serving as the issuer's Chief Financial Officer from Feb 1, 2026 through Jan 31, 2027.
• No indication in the filing of immediate sale, cashless exercise, tax-withholding, or a 10b5-1 plan.

Context: This was a compensation grant (an award of options), not an open-market purchase or sale. Such grants are common for new executives and do not by themselves indicate the insider is buying or selling stock; they reflect employment compensation. Because exercise price, vesting schedule, and other terms were not disclosed on the Form 4, investors should consult the company’s proxy statements or subsequent filings for full details if those terms are material to valuation.